Home
Therapeutic Products
Cytonics is developing the next generation in autologous treatments for osteoarthritis, back and joint pain.
Based on Cytonics’ in depth knowledge of the pain cascade and our discovery of FAC, we have developed a method to concentrate proteins that inhibit cartilage degeneration and that prevent the formation of FAC.
The Cytonics Autologous Platelet Integrated Concentration ("APIC") System is indicated for the rapid preparation of autologous platelet rich plasma/platelet poor plasma from a small sample of blood at the patient's point of care. Our APIC™ System utilizes a unique centrifugation and filtration process to deliver an optimal concentration of platelet rich, leukocyte poor APIC.
We will submit 510(k) and IND applications for FDA approval of APIC, with support from our regulatory affairs counsel, Hogan Lovells.
